WT1 and acute myeloid leukemia: To assess the background of this assay in addition to using HIV tetramer in staining, we analyzed the samples from 12 HLA-A24+ healthy donors (HDs) and 10 HLA-A24+ patients with AML who had not been treated with aAVC-WT1 (Figure S3B).